The Finnish Faecal Microbiota Transplantation Study (FINFMT)

NCT ID: NCT03732131

Last Updated: 2020-02-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-18

Study Completion Date

2029-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to follow up the long term effects of faecal microbiota tranplantation (FMT). All the over 18 years old patients receiving FMT and not included in other trials meet inclusion criteria to this study. Patients will be asked for a written consent. The outcome and possible side effects of the FMT will be followed by blood and feces samples for one year and with questionaires up to ten years after the FMT.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Faecal Microbiota Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \> 18 years age
* receiving FMT for rCDI or any other madical condition
* written consent
* Not included in other FMT trials

Exclusion Criteria

* Unable to provide written consent
* \< 18 years age
* Included in other FMT-trial
Minimum Eligible Age

18 Years

Maximum Eligible Age

120 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Helsinki

OTHER

Sponsor Role collaborator

Helsinki University Central Hospital

OTHER

Sponsor Role collaborator

Turku University Hospital

OTHER_GOV

Sponsor Role collaborator

Tampere University Hospital

OTHER

Sponsor Role collaborator

Oulu University Hospital

OTHER

Sponsor Role collaborator

Kuopio University Hospital

OTHER

Sponsor Role collaborator

South Karelia, Social and Health Care District

OTHER

Sponsor Role collaborator

North Karelia Central Hospital

OTHER

Sponsor Role collaborator

Keski-Pohjanmaa Central Hospital

UNKNOWN

Sponsor Role collaborator

Seinajoki Central Hospital

OTHER

Sponsor Role collaborator

Jyväskylä Central Hospital

OTHER

Sponsor Role collaborator

Kanta-Häme Central Hospital

OTHER_GOV

Sponsor Role collaborator

Mikkeli Central Hospital

OTHER

Sponsor Role collaborator

Vaasa Central Hospital, Vaasa, Finland

OTHER

Sponsor Role collaborator

Lapland Central Hospital

UNKNOWN

Sponsor Role collaborator

Satakunta Central Hospital

OTHER

Sponsor Role collaborator

Kymenlaakso Social and Health Services

UNKNOWN

Sponsor Role collaborator

Kainuu Social and Health Care Joint Authority

OTHER

Sponsor Role collaborator

Joint Authority for Päijät-Häme Social and Health Care

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Perttu Arkkila, PhD

Role: STUDY_DIRECTOR

Head of Department

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Joint Authority for Päijät-Häme Social and Health Care

Lahti, , Finland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Finland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Perttu Lahtinen, MD

Role: CONTACT

+358-3-819 11

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Perttu Lahtinen, MD

Role: primary

+358-3-81911

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HUS/3198/2017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.